The India giant cell arteritis (GCS) treatment market was valued at USD 1.86 Million in 2025. It is expected to grow at a CAGR of 5.00% during the forecast period of 2026-2035 and attain a market value of USD 3.03 Million by 2035 driven by growing clinical expertise in rheumatology and improved access to diagnostic imaging across major hospitals in the region. Additionally, rising awareness among physicians, expanding healthcare coverage for elderly populations, and ongoing clinical studies that are introducing advanced therapies are driving market growth.
Base Year
Historical Period
Forecast Period
Growing geriatric population and improved diagnostic imaging are driving early detection and GCA treatment expansion in urban regions.
Rising adoption of biologics and corticosteroid-sparing therapies is enhancing long-term disease management outcomes across specialized centers.
Major market trends include an increased awareness among general physicians is expected to boost referrals and diagnosis rates in tier-2 and tier-3 Indian cities.
Compound Annual Growth Rate
5%
Value in USD Million
2026-2035
*this image is indicative*
Giant cell arteritis (GCA) is an inflammatory vascular disease affecting medium to large arteries, primarily in individuals over 50. In India, delayed diagnosis is common due to limited awareness and overlapping symptoms with other conditions, leading to complications like vision loss or stroke. However, growing access to rheumatology care, improved diagnostic imaging, and availability of corticosteroids and biologics are strengthening treatment options. Early intervention is key to managing inflammation and preventing irreversible damage among at-risk elderly populations.
Growing Rheumatology Expertise to Boost Market Growth
In April 2024, over 400 rheumatologists from across India gathered at the Clinical Rheumatology Conference (CRC2024) held in Hyderabad. This collaborative event showcased case-based discussions on complex autoimmune conditions, paving the way for improved diagnosis and management of giant cell arteritis. The exchange of best practices among specialists is driving greater GCA awareness and treatment skills in India, ultimately enhancing early diagnosis and therapy adoption during the forecast period.
Major market trend includes biosimilar innovations and heightened disease awareness.
Biosimilar Advancements Accelerating India Giant Cell Arteritis Treatment Market Growth
In June 2023, Dr. Reddy’s announced successful Phase I trial results for its tocilizumab biosimilar administered intravenously. This milestone underscores increasing biosimilar development efforts in India, enhancing affordability and accessibility for Giant Cell Arteritis treatments. The dual formulation strategy supports personalized care, which is expected to accelerate market growth by meeting diverse patient needs and improving treatment outcomes across India’s expanding healthcare sector.
Rising Prevalence and Awareness to Boost India Giant Cell Arteritis Treatment Market Demand
A multicenter collaborative study published in November 2023 examined the clinical profiles of giant cell arteritis (GCA) patients in India. This study underscored the increasing recognition of GCA among healthcare professionals, highlighting a rising awareness of the condition. Such awareness is crucial for early diagnosis and timely treatment, which can significantly improve patient outcomes and reduce the risk of complications like vision loss.
Corticosteroids Leading the Segment by Drug Type in India GCA Market
Corticosteroids are expected to hold the largest market share due to their role as the first-line therapy. They offer rapid inflammation control and help prevent serious complications like vision loss and stroke, which are common risks with delayed treatment. As per the analysis by Expert Market Research, the giant cell arteritis treatment is expected to grow at a CAGR of 5.20% during the forecast period of 2025-2034. Their affordability, widespread clinical use, and physician familiarity further support dominance in the Indian market, where early and accessible intervention is crucial in managing GCA among the aging population.
The Western region is likely to hold the largest share due to its higher elderly population density and greater access to specialized rheumatology services in states like Maharashtra and Gujarat. Advanced diagnostic infrastructure and urban health awareness also support early intervention. While the Southern region is emerging with improving healthcare networks, Northern and Central regions face challenges in specialist availability. The Eastern region continues to see lower diagnosis rates, limiting market penetration.
The key features of the market report comprise clinical trials analysis, patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Headquartered in Basel, Switzerland, F. Hoffmann-La Roche Ltd. was established in 1896 and is a global leader in biotechnology and diagnostics. In the India Giant Cell Arteritis (GCA) treatment market, Roche offers biologics such as tocilizumab, an IL-6 inhibitor approved for GCA, which has shown significant success in reducing corticosteroid dependence. The company’s strong clinical research infrastructure and presence in India enhance its portfolio's reach in managing chronic inflammatory conditions like GCA effectively.
Organon & Co., headquartered in Jersey City, New Jersey, was established in 2021 as a spin-off from Merck & Co. The company focuses on women’s health, biosimilars, and established medicines. In India’s GCA treatment market, Organon provides access to corticosteroids and immunomodulators, integral to managing vascular inflammation. Its expanding biosimilars pipeline, combined with strategic partnerships across India, supports its presence in chronic autoimmune therapies, contributing to improved access and affordability of treatments for Giant Cell Arteritis.
AbbVie Inc., headquartered in North Chicago, Illinois, was founded in 2013 following its spin-off from Abbott Laboratories. The company is a leader in immunology, oncology, and neuroscience. In India, AbbVie plays a significant role in the GCA treatment market through its immunosuppressive and biologic therapies, including IL-6 and TNF inhibitors. Its robust research capabilities and established rheumatology portfolio position it as a major contributor to long-term disease management strategies for patients suffering from Giant Cell Arteritis.
Merck & Co., Inc., known as MSD outside the US and Canada, is headquartered in Rahway, New Jersey, and was founded in 1891. The company is known for its broad therapeutic portfolio, including vaccines and chronic disease treatments. In India’s GCA treatment landscape, Merck contributes through corticosteroids and supportive therapies often used in combination with other agents. Its legacy in autoimmune disease management and growing partnerships in India support the market’s evolving clinical and access needs.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Macleods Pharmaceuticals Pvt Ltd, Univentis Medicare Ltd, and Cipla Ltd.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Drug Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by Region
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share